Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.

Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level.

[Retrospective census of cancers between 1994 and 2002 around the municipal solid waste incinerator of Gilly-sur-Isère].

Background: The retrospective cancer incidence study carried out around the municipal solid waste incinerator of Gilly-sur-Isère (Savoie, France) was ordered in a context of crisis during its closing in the late 2001. Its purpose was to determine whether or not there was an excessive number of cancers around the incinerator. In the absence of cancer registry in Savoie, this study consisted in counting as exhaustively as possible the cancers that occurred between 1994 and 2002 in the study area, which was exposed to the atmospheric fallouts from the incinerator.

[The "Compli'Asthme" therapeutic observation survey on good use of inhaled drugs for asthma: perception by general practitioners].

A cross sectional survey was conducted in 2000 in coordination with the CHIESI medical representatives among 1758 French physicians caring for patients with persistent asthma (80% general practitioners, 20% specialists). This "Compli'Asthme" survey was based on a self-administered questionnaire designed to learn more about the physicians' experience with good use of inhaled drugs and to collect information on therapeutic observance, corticophobia, and use of prescribed inhalers. Poor observance was noted as an important problem by 58-85% of the participants.

Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV).

Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences.

Design: A decision-analysis model. The probability of progression of the infection and of its associated care, the principal direct costs linked to them, and the effectiveness of OM-85 BV were established or calculated by reviewing the available literature (published between 1984 and 2000).